Viking Therapeutics, Inc. (NASDAQ:VKTX – Get Free Report) was the recipient of unusually large options trading activity on Friday. Stock investors bought 14,110 call options on the company. This is an increase of approximately 172% compared to the typical daily volume of 5,181 call options.
Viking Therapeutics Trading Down 1.5 %
Shares of NASDAQ VKTX opened at $14.77 on Friday. The firm’s 50-day moving average is $14.58 and its 200-day moving average is $16.97. Viking Therapeutics has a 1 year low of $2.53 and a 1 year high of $25.72. The firm has a market capitalization of $1.48 billion, a PE ratio of -16.23 and a beta of 0.52.
Viking Therapeutics (NASDAQ:VKTX – Get Free Report) last released its quarterly earnings data on Wednesday, July 26th. The biotechnology company reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.02. During the same quarter in the prior year, the business posted ($0.23) EPS. The company’s revenue for the quarter was up .0% compared to the same quarter last year. As a group, equities research analysts anticipate that Viking Therapeutics will post -0.91 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Analyst Upgrades and Downgrades
VKTX has been the topic of a number of research analyst reports. Stifel Nicolaus reissued a “buy” rating and set a $30.00 price objective on shares of Viking Therapeutics in a report on Tuesday, August 8th. StockNews.com raised shares of Viking Therapeutics to a “sell” rating in a research note on Friday, September 8th. Finally, Roth Capital reaffirmed a “buy” rating on shares of Viking Therapeutics in a research note on Tuesday, May 30th. One analyst has rated the stock with a sell rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $30.25.
About Viking Therapeutics
Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.
- Five stocks we like better than Viking Therapeutics
- How to Read Stock Charts for Beginners
- China’s Jump In Car Sales Is Drawing Big Money To These Stocks
- Technology Stocks Explained: Here’s What to Know About Tech
- 3 Reasons Price Weakness Is a Buying Opportunity For Lennar
- Investing in Construction Stocks
- Name A Better Trio Than These Underrated High Potential Stocks
Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.